Related Experiment Video
Updated: Jan 25, 2026

Determination of Reproductive Competence by Confirming Pubertal Onset and Performing a Fertility Assay in Mice and Rats
Published on: October 13, 2018
Letrozole Monotherapy in Pre- and Early-Pubertal Boys Does Not Increase Adult Height
Tero Varimo1, Sanna Toiviainen-Salo2, Taneli Raivio1,3
1Pediatric Research Center, Children's Hospital, Helsinki University Hospital, Helsinki, Finland.
Insights
Aromatase inhibitors (AIs) did not improve adult height in boys with idiopathic short stature (ISS). Long-term follow-up confirmed similar adult heights and vertebral deformity rates between AI-treated and placebo groups, indicating no significant benefit or harm.
Area of Science:
- Pediatric Endocrinology
- Growth Disorders
- Pharmacological Interventions
Background:
- Aromatase inhibitors (AIs) are used off-label for idiopathic short stature (ISS) in boys.
- Limited data exist on the long-term effects of AIs on adult height in this population.
Purpose of the Study:
- To evaluate adult height outcomes in boys with ISS treated with letrozole (Lz) or placebo (Pl).
- To assess long-term skeletal safety and vertebral deformity changes following AI treatment.
Main Methods:
- Randomized, double-blind, placebo-controlled trial involving boys treated with Lz or Pl for 2 years.
- Adult height and spine MRI data were collected for long-term follow-up.
- Bone age was assessed at treatment cessation.
Main Results:
- Adult heights were comparable between the Lz and Pl groups (164.8 cm vs. 163.7 cm).
- Adult heights in both groups did not significantly differ from predicted adult heights at baseline.
- Vertebral deformity frequencies were similar between groups (29% Lz vs. 22% Pl), with no clear enrichment of comorbidities.
Conclusions:
- Letrozole treatment did not significantly improve adult height in pre- or early-pubertal boys with ISS.
- Previously observed vertebral deformities showed amelioration during follow-up.
- Letrozole therapy appears to be skeletally safe in children and adolescents with ISS.
Abstract:
Background: Aromatase inhibitors (AIs) have been used in boys with idiopathic short stature (ISS) to promote growth despite the lack of actual data regarding treatment effect on adult height. In this study, we characterized adult heights and long-term follow-up in AI-treated boys with ISS. Methods: Adult heights and long-term follow-up data, including spine MRIs, of a randomized, double-blind, placebo-controlled trial of boys who were treated with letrozole (Lz) (2.5 mg/d) or placebo (Pl) for 2 years during prepuberty and early puberty. The mean bone ages at treatment cessation were 10.2 and 10.8 years, respectively. Results: Adult heights were similar between the boys treated with Lz (n = 10) and those who received Pl (n = 10) (164.8 ± 4.0 vs. 163.7 ± 3.7 cm, p = 0.49, respectively). In either group, the adult heights did not differ from predicted adult heights at start of the study [Pl: 163.7 (3.7) cm vs. 166.9 (3.3), p = 0.06; Lz: 164.8 (4.0) cm vs. 167.6 (7.9), p = 0.20, respectively]. Long-term follow-up data showed that the frequency of subjects with a vertebral deformity was similar between the groups (Lz, 29% and Pl, 22%, p = 0.20), and no single comorbidity was clearly enriched in either group. Conclusions: The Lz-treated boys had similar adult heights with the subjects who received Pl for 2 years, which indicates that the treatment is not beneficial when given to pre- or early-pubertal boys. Previously observed vertebral deformities ameliorated during follow-up, which supports the skeletal safety of Lz therapy in children and adolescents.
More Related Videos
Related Concept Videos
pre-mRNA Processing
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl...
Pre-mRNA Processing: Modification of pre-mRNA Ends
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a cap to the 5' end of the growing transcript. In this process, a 5' phosphate is replaced by modified guanosine that has a methyl group attached (7-methyl guanosine). This 5' cap helps...
Increased Body Temperature
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Adult Stem Cells

